drugset / Trial / NCT02997059

Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.

NCT02997059

RandomizedParallel-groupDouble-blindTreatment

Summary

This was prospective study randomized in two controlled parallel groups verum versus placebo. The objectives were to assess the influence of antifungal treatment with Fluconazole (FCZ) on the rate of ASCA and endoscopic recurrence at 6 months. The rational was based on our previous research having established i) a link between intestinal inflammation and the opportunistic fungal pathogen C. albicans -a yeast colonizing the human digestive tract- ii) the demonstration that this yeast species could be at the origin of ASCA, a prominent serological marker of CD. It was therefore hypothesized that the FCZ could lower the rate of ASCA and/or reduce the occurrence of recurrences.

Timeline

Start
2008-07
Primary completion
2014-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluconazole Small molecule 200 mg

Indications